跳至主要内容
临床试验/NL-OMON55536
NL-OMON55536已完成4 期

Deep profiling of lipid changes in patients with active ulcerative colitis treated with either tofacitinib or infliximab - LIPID study

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Aged 18 years or older
  • - Previous diagnosis with ulcerative colitis of at least 3 months
  • - Moderately to severe disease defined as SCCAI equal or more than 5 and fecal
  • calprotectine more than 250 ug/g
  • - Refractory disease or intolerance for 5-ASA, thiopurines and/or biologicals
  • - Body mass index of 20-35 kg/m2

排除标准

  • - Absence of written informed consent
  • - Active or current infection
  • - Current treatment with biologicals (wash-out 8 weeks)
  • - Concomitant medication use to be named corticosteroids (except for locally
  • administered or low dose systemic corticosteroids, e.g. prednisone <20mg and
  • budesonide <9mg), lipidregulating agents, supplements with involved in
  • cholesterol metabolism
  • - Pregnancy and lactation
  • - Concomitant disease to be named diabetes, hypo- or hyperthyroeidism, liver or
  • renal failure, adrenal failure, hyperlipidemia, hypoalbuminemia,
  • cardiopulmonary disease, malignancy, immunodeficiency, psychiatric illnesses

研究者

相似试验

Deep profiling of lipid changes in patients with... | 临床试验